Abstract
FDA has approved olodaterol (Striverdi Respimat—Boehringer Ingelheim), a once-daily inhalation spray to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The long-acting beta-adrenergic agonist (LABA), delivered via a propellant-free inhaler, helps the muscles around the airways in the lungs stay relaxed to prevent symptoms.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
